Divis Laboratories Share Price

Divi’s Laboratories Ltd is a Hyderabad-based pharmaceutical company. It is a leading manufacturer of active pharmaceutical ingredients (APIs) and supplies its products to more than 100 countries. The company which is counted among the top API manufacturers in the world has been operating for the last 30 years.

Divi’s started as Divi’s Research Centre (DRC) in 1990. It set up its first manufacturing unit in Hyderabad in 1995 and received the USFDA inspection for the first time in 2000. The company set up its second manufacturing unit near Vishakhapatnam in 2002 and a year later was listed on BSE and NSE.

The company entered into the nutraceuticals segment in 2007. It also set up a new research unit in Hyderabad in 2010.

At present, Divi’s Laboratories has 16,500 trained professionals across departments and around 400 scientists working at its three research centres. It has two manufacturing facilities at Vizag and Hyderabad.

Business highlights

Divi’s Lab has a market valuation of Rs 98,600 crore as of December 19, 2023. Divi’s Lab shares price has dropped nearly 3% in three years.

The company’s business operations span across research and development activities and manufacturing operations. Its two main manufacturing facilities in Vizag and Hyderabad produce thousands of tonnes of APIs that are exported to around 100 countries.

Divi’s Laboratories have three main business segments:

Generic APIs

Divi’s Laboratories offers 30 generic active pharmaceutical ingredients to customers across the world. Its operations are bolstered by backward integration to basic starting materials, devoted production blocks with large batch sizes and significant capacity creation.

The company is a global leader in large-volume generic APIs. It looks to achieve global leadership in molecules and around 10 APIs are in the research and development stage. Its manufacturing plants have been audited by various regulatory authorities, as well as global environmental, health and safety teams.

Customs Synthesis

Divi’s Laboratories is involved in contract manufacturing services (custom synthesis) of APIs and intermediates for global companies. It has a portfolio of products across diverse therapeutic areas. The company has 12 out of the top 20 big pharma companies across US, Europe and Japan as its customers for more than 10 years.

Divi’s being a core generic API manufacturer has a research and development (R&D) team of more than 400 scientists.

Nutraceutical

The nutraceutical plant of Divi’s Laboratories is an integrated facility for the production of API and finished forms of Carotenoids. The company supplies carotenoids to major food, dietary supplement and feed manufacturers around the world.

Financial Highlights

Divi's Laboratories consolidated total income was ₹8,112 crore for FY23 against ₹9074 crore in FY22, a fall of 11% year-on-year. Total expenses were ₹ 5,620 crore in FY23 against ₹ 5315 crore in FY22. Divi's reported profit before tax of ₹2,369 crore for FY23 against ₹ 3,684 crore for the previous year. Profit after tax in FY23 was ₹1,823 crore against ₹2,960 crore in FY22.

17 September 2025 – Divis Laboratories Share Price Update

As of last trading day, Divis Laboratories opened at ₹6,125.00 and last traded at ₹6,099.50, showing a rise of 42.50 points (0.70%) compared to the previous close of ₹6,057.00. During the session, the stock touched a high of ₹6,175.00 and a low of ₹6,060.50. The company's market capitalization now stands at ₹1,60,794 Crs, with a P/E ratio of 69.3 and a dividend yield of 0.52%.